Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Highly differential count of circulating and tumor infiltrating immune cells in patients with non-HCV/non-HBV hepatocellular carcinoma
Beteiligte:
Schoenberg, Markus Bo;
Zhu, Tong;
Hao, Jingcheng;
Bucher, Julian Nikolaus;
Li, Xiaokang;
Li, Xinyu;
Han, Yongsheng;
Koliogiannis, Dionysios;
Svihla, Michaela;
Guba, Markus Otto;
Werner, Jens;
Bazhin, Alexandr V.
Erschienen:
Springer Science and Business Media LLC, 2022
Erschienen in:
Cancer Immunology, Immunotherapy, 71 (2022) 5, Seite 1103-1113
Sprache:
Englisch
DOI:
10.1007/s00262-021-03061-9
ISSN:
0340-7004;
1432-0851
Entstehung:
Anmerkungen:
Beschreibung:
Abstract Background Liver transplantation and liver resection are curative options for early hepatocellular carcinoma (HCC). The outcome is in part depended on the immunological response to the malignancy. In this study, we aimed to identify immunological profiles of non-HCV/non-HBV HCC patients. Methods Thirty-nine immune cell subsets were measured with multicolor flow cytometry. This immunophenotyping was performed in peripheral blood (PB) and tumor specimens of 10 HCC resection patients and 10 healthy donors. The signatures of the highly differential leukocyte count (hDIF) were analyzed using multidimensional techniques. Functional capability was measured using intracellular IFN-γ staining (Trial Registration DRKS00013567). Results The hDIF showed activation (subsets of T-, B-, NK- and dendritic cells) and suppression (subsets of myeloid-derived suppressor cells and T- and B-regulatory cells) of the antitumor response. Principal component analysis of PB and tumor infiltrating leukocytes (TIL) illustrated an antitumor activating gradient. TILs showed functional capability by secreting IFN-γ but did not kill HCC cells. Conclusions In conclusion, the measurement of the hDIF shows distinct differences in immune reactions against non-HBV/non-HCV HCC and illustrates an immunosuppressive gradient toward peripheral blood. Trial Registration DRKS00013567